Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609
-
Published:2022-08-27
Issue:1
Volume:32
Page:183-196
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
McLouth Laurie E.ORCID, Zheng Yue, Smith Stephanie, Hodi F. Stephen, Rao Uma N., Cohen Gary I., Amatruda Thomas T., Dakhil Shaker R., Curti Brendan D., Nakhoul Ibrahim, Chandana Sreenivasa R., Bane Charles L., Marinier David E., Lee Sandra J., Sondak Vernon K., Kirkwood John M., Tarhini Ahmad A., Wagner Lynne I.
Funder
ECOG-ACRIN Cancer Research Group National Cancer Institute National Center for Clinical and Translational Science
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference25 articles.
1. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590 2. Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M., Marquez-Rodas, I., … Larkin, J. (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 377(14), 1345–1356. https://doi.org/10.1056/NEJMoa1709684 3. Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., ChiarionSileni, V., Schachter, J., Garbe, C., Bondarenko, I., Gogas, H., Mandala, M., Haanen, J., Lebbe, C., Mackiewicz, A., Rutkowski, P., Nathan, P. D., Ribas, A., Davies, M. A., … Long, G. V. (2019). Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. New England Journal of Medicine, 381(7), 626–636. https://doi.org/10.1056/NEJMoa1904059 4. Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F., for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. (2017). Melanoma staging: Evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67(6), 472–492. https://doi.org/10.3322/caac.21409 5. Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., Koon, H. B., Lawrence, D. P., Kendra, K. L., Minor, D. R., Lee, C. B., Albertini, M. R., Flaherty, L. E., Petrella, T. M., Streicher, H., … Kirkwood, J. M. (2020). Phase iii study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North american intergroup e1609. Journal of Clinical Oncology, 38(6), 567–575. https://doi.org/10.1200/JCO.19.01381
|
|